Preformulation studies of mucoadhesive tablets for carbamazepine sublingual administration

Colloids and Surfaces B: Biointerfaces

Volumn 102, Issue , 2013, Pages 915-922

  Perioli, Luana ^a   Pagano, Cinzia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Buccal tablets; Carbamazepine; Mucoadhesion; Polymers; Release

Indexed keywords

ACTIVE INGREDIENTS; BACKING LAYERS; BIOADHESIVE FORCE; BUCCAL MUCOSA; BUCCAL TABLETS; CARBAMAZEPINE; CARBOPOL; DOSAGE FORMS; DRUG RELEASE; ETHYL CELLULOSE; EX-VIVO; HYDROXYETHYL CELLULOSE; HYDROXYPROPYL METHYLCELLULOSE; IN-VITRO; IN-VIVO; MATRIX EROSION; METHYLCELLULOSE; MUCOADHESION; RELEASE; SUBLINGUAL ADMINISTRATION; SUSTAINED RELEASE; SWELLING INDEX; SYNTHETIC POLYMERS;

DRUG PRODUCTS; POLYMERS;

AMIDES;

CARBAMAZEPINE; CARBOMER; ETHYL CELLULOSE; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE;

ARTICLE; BILAYERED TABLET; CHEEK MUCOSA; CONTROLLED STUDY; DRUG DIFFUSION; DRUG STABILITY; EX VIVO STUDY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; MATRIX EROSION; MUCOADHESION; MUCOADHESIVE FORCE; MUCOADHESIVE TIME; NORMAL HUMAN; ORGANOLEPTIC PROPERTY; PREFORMULATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; SWELLING INDEX; TABLET; TABLET FORMULATION; TABLET FRIABILITY; TABLET MANUFACTURE; TABLET PROPERTY; TABLET THICKNESS;

ADMINISTRATION, SUBLINGUAL; CARBAMAZEPINE; HUMANS; POLYMERS; TABLETS;

EID: 84868226995     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.10.001     Document Type: Article

References (29)

1. Parfitt K. Martindale, The complete drug reference 1999, Pharmaceutical Press, London. 32th ed.
2. Lindenberg M., Kopp S., Dressman J.B. Classification of orally administered drugs on the World Health Organization model list of the essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004, 58:265-278.
3. Custodio J.M., Wu C.Y., Benet L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 2008, 60:717-733.
4. Levy R., Wilensky A.J., Anderson G.D. Carbamazepine, valproic acid, phenobarbital, and ethosuximide. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring 1992, 1-29. Applied Therapeutics, Vancouver. third ed. W.E. Evans, J.J. Jusko (Eds.).
5. Koester L.S., Bertuol J.B., Groch K.R., Xavier C.R., Moellerke R., Mayorga P., Dalla Costa T., Bassani V.L. Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur. J. Pharm. Sci. 2004, 22:201-207.
6. Giannola L.I., Caro De V., Giandalia G., Siragusa M.G., D'Angelo M., Lo Muzio L., Campisi G. Transbuccal tablets of carbamazepine: formulation, release and absorption pattern. Int. J. Immunopathol. Pharmacol. 2005, 18:21-31.
7. Andersona G.D., Saneto R.P. Current oral and non-oral routes of antiepileptic drug delivery. Adv. Drug Deliv. Rev. 2012, 64:911-918.
8. Kellaway I.W., Ponchel G., Duchêne D. Oral mucosal drug delivery. Modified Release Drug Delivery Technology 2003, 349-350. Marcel Dekker Inc., New York. M.J. Rathbone, J. Hadgraft, M.S. Roberts (Eds.).
9. Rossi S., Sandri G., Caramella C.M. Buccal drug delivery: a challenge already won?. Drug Discov. Today Technol. 2005, 2:59-65.
10. Salamat-Miller N., Chittchang M., Johnston T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005, 57:1666-1691.
11. Asane G.S., Nirmal S.A., Rasal K.B., Naik A.A., Rao M.S.M.Y.M. Polymers for mucoadhesive drug delivery system: a current status. Drug Dev. Ind. Pharm. 2008, 34:1246-1266.
12. Sudhakar Y., Kuotsu K., Bandyopadhyay A.K. Buccal bioadhesive drug delivery - a promising option for orally less efficient drugs. J. Control. Release 2006, 114:15-40.
13. Birudaraj R., Mahalingam R., Li X., Bhaskara R.J. Advances in buccal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22:295-330.
14. Patel V.F., Liu F., Brown M.B. Advances in oral transmucosal drug delivery. J. Control. Release 2011, 153:106-116.
15. Perioli L., Ambrogi V., Rubini D., Giovagnoli S., Blasi P., Rossi C. Novel mucoadhesive topical formulation containing metronidazole for the treatment of periodontal diseases. J. Control. Release 2004, 95:521-533.
16. Perioli L., Ambrogi V., Pagano C., Scuota S., Rossi C. FG90 chitosan as a new polymer for metronidazole mucoadhesive tablets for vaginal administration. Int. J. Pharm. 2009, 377:120-127.
17. Shah V.P., Konecny J.J., Everett R., McCullough C., Nooryzadeh A.C., Skelly J.P. In vitro dissolution profile of water-insoluble drug dosage forms in presence of surfactants. Pharm. Res. 1989, 6:612-618.
18. Shah V.P., Noory A., Noory C., McCullough B., Clarke S., Everett R., Naviasky H., Srinivasan B.N., Fortman D., Skelly J.P. In vitro dissolution of sparingly water soluble drug dosage forms. Int. J. Pharm. 1995, 125:99-106.
19. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for industry dissolution testing of immediate release solid oral dosage forms, (August) 1997.
20. Miyazaki S., Kawasaki N., Nakamura T., Iwatsu M., Hayashi T., Hou W.M., Attwood D. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation. Int. J. Pharm. 2000, 204:127-132.
21. Remuñán-López C., Portero A., Vila-Jato J.L., Alonso M.J. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J. Control. Release 1998, 55:143-152.
22. Qiu D.Y., Chen Y., Liu L., Zhang G.G.Z. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009, Academic Press, New York.
23. Machida Y., Nagai T. Bioadhesive preparation as topical dosage forms. Bioadhesive Drug Delivery Systems 1999, 646-647. Marcel Dekker Inc., New York. E. Mathiowitz, D.E. Chickering, C.M. Lehr (Eds.).
24. EMEA, Guideline on stability testing: stability testing of existing active substances and related finished products, CPMP/QWP/122/02, rev 1, 2003.
25. McCarthy L.G., Bradley G., Sexton J.C., Corrigan O.I., Healy A.M. Computational fluid dynamics modeling of the paddle dissolution apparatus: agitation rate, mixing patterns, and fluid velocities. AAPS PharmSciTech 2004, 5:1-10. Article 31, http://www.aapspharmscitech.org.
26. Healy A.M., McCarthy L.G., Gallagher K.M., Corrigan O.I. Sensitivity of dissolution rate to location in the paddle dissolution apparatus. J. Pharm. Pharmacol. 2002, 54:441-444.
27. Qureshi S.A., Shabnam J. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Eur. J. Pharm. Sci. 2001, 12:271-276.
28. Mirza T., Joshi Y., Liu Q., Vivilecchia R. Evaluation of dissolution hydrodynamics in the USP, Peak™ and flat-bottom vessels using different solubility drugs. Dissol. Technol. 2005, 12:11-16.
29. Ritger P., Peppas N.A. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release 1987, 5:37-42.